Synergistic antiglioma activity of radiotherapy and enzastaurin

Annals of Neurology

Volumn 61, Issue 2, 2007, Pages 153-161

  Tabatabai, Ghazaleh ^a   Frank, Brigitte ^a   Wick, Antje ^a   Lemke, Dieter ^a   Von Kürthy, Gabriele ^a   Obermüller, Ulrike ^a   Heckl, Stefan ^b   Christ, Gunter ^b   Weller, Michael ^a   Wick, Wolfgang ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENZASTAURIN; PROTEIN KINASE C BETA INHIBITOR; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER TRANSPLANTATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEASIBILITY STUDY; GLIOMA; GLIOMA CELL; GRANULE CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR VOLUME; UPREGULATION;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GLIOMA; INDOLES; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; SURVIVAL ANALYSIS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33847677276     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21057     Document Type: Article

References (21)

1. Stupp R, Mason WP, van den Bent MJ, et al, on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor and Radiotherapy Groups and National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma. N Engl J Med 2005;352:987-996.
2. Wild-Bode C, Weller M, Rimner A, et al. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 2001;61:2744-2750.
3. Wick W, Wick A, Schulz JB, et al. Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res 2002;62:1915-1919.
4. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
5. 3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005;11:6270-6279.
6. Yoshiji H, Kuriyama S, Ways DK, et al. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 1999;59:4413-4418.
7. Keyes KA, Mann L, Sherman M, et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 2004;53:133-140.
8. Graff JR, McNulty AM, Hanna RK, et al. The protein kinase Cβ-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462-7469.
9. Fine HA, Kim L, Royce C, et al. Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. Proc ASCO 2005:1504 (Abstract).
10. Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-989.
11. Hermisson M, Klumpp A, Wick W, et al. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006;96:766-776.
12. Wick A, Wick W, Hirrlinger J, et al. Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity. J Neurochem 2004;91:1067-1074.
13. Ferrari D, Villalba M, Chiozzi P, et al. Mouse microglial cells express a plasma membrane pore gated by extracellular ATP. J Immunol 1996;156:1531-1539.
14. Muruganandam A, Herx LM, Monette R, et al. Development of immortalized human cerebromicrovascular endothelial cell line as an in vitro model of the human blood-brain barrier. FASEB J 1997;11:1187-1197.
15. Tabatabai G, Frank B, Möhle R, et al. Irradiation and hypoxia promote homing of hematopoietic progenitor cells towards gliomas by TGF-β-dependent HIF-1α-mediated induction of CXCL12. Brain 2006;129:2426-2435.
16. Querfeld C, Rizvi MA, Kuzel TM, et al. The selective protein kinase C-beta inhibitor Enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the Akt-pathway. J Invest Dermatol 2006;126:1641-1647.
17. Teicher BA, Menon K, Alvarez E, et al. Antiangiongenic and antitumor effects of a protein kinase C-beta selective small molecule. Cancer Chemother Pharmacol 2002;49:69-77.
18. Pearce HL, Alice Miller M. The evolution of cancer research and drug discovery at Lilly Research Laboratories. Adv Enzyme Regul 2005;45:229-255.
19. Sledge GW, Gokmen-Polar Y. Protein kinase C-beta as a therapeutic target in breast cancer. Semin Oncol 2006;33:15-18.
20. Carducci MA, Musib L, Kies MS, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006;24:4092-4099.
21. Wischhusen J, Naumann U, Ohgaki H, et al. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent cell death. Oncogene 2003;22:8233-8245.